Slide 1 of 7
Slide 1 - Risk-Based Containment Strategy
Risk-Based Containment Strategy
A Risk-Based Case Study for Synthetic Molecule API Facilities
---
Photo by Glsun Mall on Unsplash
Risk-Based Containment Strategy for API Facilities
Generated from prompt:
Regenerate the presentation "Risk-Based Containment Strategy – A Case Study for Synthetic Molecule API Facility" with the same improved modern design, ensuring the file is immediately downloadable. Keep all previous enhancements (modern pharma theme, icons, diagrams, concise bullets, strong visual hierarchy, highlighted metrics like <0.05 μg/m³ and 100% compliance).
Explore a science-driven, risk-based approach to containment in synthetic molecule API manufacturing. Covers strategic framework, multi-layered engineering/administrative/PPE solutions, performance metrics, implementation workflow, and commitment to
March 20, 20267 slides
Slide 2 of 7
Slide 2 - Agenda
- Strategic Framework: Understanding the risk-based approach for high-potency APIs.
- Containment Solutions: Engineering, administrative, and PPE controls for safety.
- Performance Metrics: Data on exposure limits and regulatory adherence.
- Compliance and Sustainability: Ensuring safety and operational excellence.
---
Photo by Simeon Galabov on Unsplash
Slide 3 of 7
Slide 3 - Strategic Framework
- Focus on protecting personnel from exposure to potent synthetic molecules.
- Shift from conventional to risk-based, science-driven containment.
- Alignment with global occupational exposure limit (OEL) standards.
- Integration of primary and secondary containment strategies.
Slide 4 of 7
Slide 4 - Multi-Layered Containment Solutions
⚙️ Engineering Controls Isolators, RABS, and closed transfer systems for source control.
📝 Administrative Controls Standard Operating Procedures and personnel training.
🛡️ Personal Protective Equipment (PPE) Specialized respiratory and chemical-resistant suits.
Slide 5 of 7
Slide 5 - Performance and Safety Metrics
- <0.05μg/m³: Exposure Target
- 100%: Compliance Rate
- 45%: Safety Improvement
Slide 6 of 7
Slide 6 - Implementation Workflow
| Phase | Key Actions |
|---|---|
| Design Phase | Hazard assessment and containment definition. |
| Implementation | Installation of advanced isolator technology. |
| Validation | Air sampling and rigorous safety testing. |
| Monitoring | Real-time oversight and continuous improvement. |
Slide 7 of 7
Slide 7 - Conclusion
Commitment to Absolute Safety and Compliance
Driving excellence in pharmaceutical manufacturing safety.
Discover More Presentations
Explore thousands of AI-generated presentations for inspiration
Powered by AI
Create Your Own Presentation
Generate professional presentations in seconds with Karaf's AI. Customize this presentation or start from scratch.